Compare EQBK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | ARDX |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.9M | 797.8M |
| IPO Year | 2015 | 2014 |
| Metric | EQBK | ARDX |
|---|---|---|
| Price | $48.83 | $2.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $54.14 | $12.80 |
| AVG Volume (30 Days) | 110.7K | ★ 4.0M |
| Earning Date | 10-14-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $29.42 | $19.60 |
| Revenue Next Year | $21.36 | $28.11 |
| P/E Ratio | $23.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.98 | $2.99 |
| 52 Week High | $52.27 | $8.40 |
| Indicator | EQBK | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 32.91 |
| Support Level | $48.53 | N/A |
| Resistance Level | $48.80 | $3.35 |
| Average True Range (ATR) | 1.14 | 0.13 |
| MACD | 0.30 | 0.00 |
| Stochastic Oscillator | 75.75 | 2.67 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.